IRIS
MARTINI, Giulia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.131
NA - Nord America 931
AS - Asia 211
OC - Oceania 2
Totale 2.275
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 919
IE - Irlanda 469
IT - Italia 263
DE - Germania 114
SG - Singapore 93
GB - Regno Unito 74
CN - Cina 60
UA - Ucraina 53
FR - Francia 50
SE - Svezia 27
GR - Grecia 24
FI - Finlandia 23
KR - Corea 16
CA - Canada 12
PK - Pakistan 12
TR - Turchia 12
CZ - Repubblica Ceca 11
BE - Belgio 7
IN - India 6
VN - Vietnam 6
NL - Olanda 5
AT - Austria 4
HK - Hong Kong 3
AU - Australia 2
CH - Svizzera 2
ES - Italia 2
GI - Gibilterra 2
HU - Ungheria 1
IR - Iran 1
JP - Giappone 1
LK - Sri Lanka 1
Totale 2.275
Salva come PNG Salva come JPEG
Città #
Dublin 459
Chandler 220
Jacksonville 94
New York 64
Singapore 57
Bremen 55
Princeton 54
Roxbury 54
Naples 52
Beijing 33
Ann Arbor 30
Cambridge 30
Caserta 24
Medford 24
Munich 24
Seoul 16
Los Angeles 14
Rome 12
Ashburn 11
Boardman 11
Brno 11
Des Moines 11
Elora 11
Wilmington 11
Napoli 9
Lappeenranta 8
Brussels 7
Helsinki 7
Milan 7
Dong Ket 6
Jinan 6
San Mateo 6
Woodbridge 6
Bahawalpur 5
Battipaglia 5
Mountain View 5
Nanjing 5
Houston 4
Pozzuoli 4
Vienna 4
Ercolano 3
Norwalk 3
Acerra 2
Anantapur 2
Andover 2
Auburn Hills 2
Avellino 2
Benevento 2
Cinquevie 2
Corbara 2
Delhi 2
Fairfield 2
Florence 2
Groningen 2
Hong Kong 2
Madrid 2
Matera 2
Menlo Park 2
San Nicola la Strada 2
Strasbourg 2
Taizhou 2
Venice 2
Volta Mantovana 2
Zurich 2
Amsterdam 1
Antea 1
Bari 1
Berlin 1
Bezons 1
Cercola 1
Düsseldorf 1
Falconara Marittima 1
Formello 1
Galatone 1
Genova 1
Giugliano in Campania 1
Guangzhou 1
Gunzenhausen 1
Kai Tak 1
Konya 1
L'aquila 1
Lviv 1
Maharagama 1
Marcianise 1
Marigliano 1
Melbourne 1
Miami 1
Nola 1
Paola 1
Paris 1
Pune 1
Ragusa 1
Redwood City 1
Sant'Antimo 1
Scafati 1
Seregno 1
Somma Vesuviana 1
Sortino 1
Tappahannock 1
Torino 1
Totale 1.562
Salva come PNG Salva come JPEG
Nome #
EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving anti-epidermal growth factor receptor therapy in colorectal cancer 101
Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. 86
Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells 86
Clinical practice use of liquid biopsy to identify RAS/BRAF mutations in patients with metastatic colorectal cancer (mCRC): A single institution experience 79
AXL is an oncotarget in human colorectal cancer 65
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience 59
Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment 58
Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme 54
Beyond N staging in colorectal cancer: Current approaches and future perspectives 50
Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case 48
Present and future of metastatic colorectal cancer treatment: A review of new candidate targets 47
Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the Covid-19 Pandemic 47
Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype 45
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial 45
Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. 44
Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy? 44
Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer 43
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer 42
Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFRdependent and in cetuximab-resistant human colorectal cancer cells 41
Genetic Landascape of Primary versus metastatic colorectal cancer: to what extent are they concordant ? 40
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab 40
Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines 39
ROLE OF THE HEDGEHOG PATHWAY IN MEDIATING RESISTANCE TO ANTI-EGFR TYROSINE KINASE INHIBITORS IN NON SMALL CELL LUNG CANCER 37
Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models 37
Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gastrointestinal Tract: A Case Series 37
Biomarker-guided anti-egfr rechallenge therapy in metastatic colorectal cancer 36
Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review 36
Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy 35
Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer 35
Cetuximab rechallenge plus avelumab in pretreated patients with RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial 35
Multi-Omic Approaches in Colorectal Cancer beyond Genomic Data 35
Immunotherapy for head and neck cancer: Present and future 35
Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials 34
Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation 34
How immunotherapy has changed the continuum of care in hepatocellular carcinoma 34
Cancer cells adapt FAM134B/BiP mediated ER-phagy to survive hypoxic stress 33
BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer 32
Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives 32
Clinical management of metastatic colorectal cancer in the era of precision medicine 32
Immunotherapy in colorectal cancer: is the long-awaited revolution finally happening? 31
CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients 30
Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression 30
Skin toxicity as predictor of survival in refractory patients with ras wild‐type metastatic colorectal cancer treated with cetuximab and avelumab (Cave) as rechallenge strategy 30
Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives 29
Pimasertib hydrochloride 28
Feasibility of next-generation sequencing in clinical practice: Results of a pilot study in the Department of Precision Medicine at the University of Campania ' Luigi Vanvitelli' 27
Implication of the Hedgehog pathway in hepatocellular carcinoma. 26
Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed? 24
How I treat anal squamous cell carcinoma 24
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM) 23
Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer 23
The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer 23
Antitumor efficacy of dual blockade with encorafenib plus cetuximab in combination with chemotherapy in human BRAFV600E mutant colorectal cancer 23
Establishment of patient-derived tumor organoids to functionally inform treatment decisions in metastatic colorectal cancer 21
Correction: Ciardiello et al. Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer. Cancers 2021, 13, 1941 20
Evaluating trifluridine + tipiracil hydrochloride in a fixed combination (TAS-102) for the treatment of colorectal cancer 19
Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial 18
Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC 17
Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS-mutant metastatic colorectal cancer 17
Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data 17
Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival. 16
RNF43- And NOTCH1-mutated chemotherapy and Anti-EGFR-refractory colorectal cancer: Should clonality guide target prioritization with investigational therapies? 16
Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer: an update 15
Case report of unusual synchronous anal and rectal squamous cell carcinoma: clinical and therapeutic lesson 14
Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer 14
Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wild type tumors at start of first line: The CAPRI 2 GOIM trial 13
A Comprehensive Biomarker Analysis of Microsatellite Unstable/Mismatch Repair Deficient Colorectal Cancer Cohort Treated with Immunotherapy 12
Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments 11
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials 10
Alarming Drop in Early Stage Colorectal Cancer Diagnoses After COVID-19 Outbreak: A Real-World Analysis from the Italian COVID-DELAY Study 8
Totale 2.421
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13.090
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.090
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020130 0 0 0 7 14 5 27 9 22 27 16 3
2020/2021184 13 11 18 8 18 1 21 21 12 22 28 11
2021/2022399 8 12 7 7 78 9 33 7 20 48 48 122
2022/2023939 99 17 25 71 125 78 4 41 426 8 26 19
2023/2024460 49 22 13 19 135 74 17 16 7 5 35 68
2024/2025115 42 38 29 6 0 0 0 0 0 0 0 0
Totale 2.421